After opening the day marginally lower, share markets in India continued to witness selling pressure in the afternoon session and ended the day in red. Losses were seen across most sectors with stocks in the pharma sector and stocks in the FMCG sector, leading the losses. While stocks in the witnessed buying interest.
At the closing bell, the BSE Sensex stood lower by 148 points (down 0.5%) and the NSE Nifty closed lower by 36 points (down 0.4%). The BSE Mid Cap index ended the day up by 0.2%, while the BSE Small Cap index ended the day up by 0.4%.
Asian stock markets finished lower over geopolitical tensions stemming from North Korea. As of the most recent closing prices, the Hang Seng was lower marginally by 0.5% and the Shanghai Composite was flat. The Nikkei 225 was down by 0.2%. European markets too were trading marginally in red. The FTSE was 100 off by 0.5%. The DAX was lower by 0.1% while the CAC 40 was down by 0.2%.
The rupee was trading at Rs 64.13 against the US$ in the afternoon session. Oil prices were trading at US$ 48.89 at the time of writing.
In news from pharma sector Dr. Reddy’s Laboratories share price was in focus today> after it launched Metaxalone Tablets, USP 800 mg, approved by the US Food and Drug Administration (USFDA).
The tablets are a therapeutic equivalent generic version of Skelaxin (metaxalone) Tablets.
Meanwhile, the company has also launched Bupropion Hydrochloride Extended-Release Tablets, USP (XL), 150 mg and 300 mg.
The drug is a therapeutic equivalent generic version of Wellbutrin XL (Bupropion Hydrochloride Extended-Release) Tablets.
According to according to IMS Health sales data, the Skelaxin brand and generics had US sales of approximately US$139 million while Wellbutrin XL brand and generics had US sales of approximately US$754 million for the most recent twelve months ending in July 2017.
